Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"

Liver Cancer. 2024 May 6;13(6):671-673. doi: 10.1159/000539205. eCollection 2024 Dec.

¹ Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
² Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
³ Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
⁴ Department of Gastroenterology, Kurume University Hospital, Kurume, Japan.
⁵ Department of Biometrics, Chugai Pharmaceutical Ltd, Tokyo, Japan.
⁶ Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

No abstract available

Keywords: Adverse events of special interest; Atezolizumab; Bevacizumab; Skipped bevacizumab; Unresectable hepatocellular carcinoma.

Grants and funding

This study was sponsored by F. Hoffmann-La Roche Ltd. Third-party medical writing assistance was sponsored by Chugai Pharmaceutical Co. Ltd.